Coexistence of BRAF V600E-Mutated Erdheim-Chester Disease with PDGFRβ- Rearranged Hypereosinophilic Syndrome: Diagnostic and Therapeutic Challenges

Erdheim-Chester disease (ECD) is a rare systemic histiocytosis driven by MAPK-pathway mutations, most frequently BRAFV600E. Myeloid neoplasms occur in 10-15% of ECD patients. This is the first report of ECD associated with clonal hypereosinophilic syndrome (HES) in the same patient.A 66-year-old woman was diagnosed with ECD harboring a BRAFV600E mutation concomitantly with HES driven by a TNIP1::PDGFRβ fusion identified by optical genome mapping (OGM). She presented with cutaneous lesions, lymphadenopathy, hypereosinophilia and pulmonary hypertension. Interferon-alpha was discontinued because of disease progression and worsening pulmonary hypertension. Imatinib was attempted but poorly tolerated, resulting in acute heart failure. Cobimetinib resulted in clinical and metabolic improvement of ECD, with limited effect on eosinophilia. Pulmonary hypertension improved after adding tadalafil and bosentan.This case illustrates the interplay between histiocytosis and a coexisting myeloproliferative neoplasm, driven by distinct molecular alterations. BRAF inhibition may cause paradoxical MAPK activation and progression in PDGFRβ-rearranged cells, whereas MEK inhibition with cobimetinib provided an effective and well-tolerated alternative for ECD. OGM was essential for identifying PDGFRβ rearrangement and guiding therapy.We report the first reported case BRAFV600E-mutated ECD associated with HES due to PDGFRβ rearrangement, emphasizing the importance of comprehensive molecular profiling and the therapeutic challenges of managing concurrent clonal hematologic disorders.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11614654/v1
Primary Topic
Histiocytic Disorders and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Coexistence of BRAF V600E-Mutated Erdheim-Chester Disease with PDGFRβ- Rearranged Hypereosinophilic Syndrome: Diagnostic and Therapeutic Challenges

Élise Chapiro, Faten Hsoumi, Nasséra Abermil, Raphaël Degrave et al.
1 links
Research Square
Histiocytic Disorders and Treatments
preprint

Coexistence of BRAF V600E-Mutated Erdheim-Chester Disease with PDGFRβ- Rearranged Hypereosinophilic Syndrome: Diagnostic and Therapeutic Challenges

Élise Chapiro, Faten Hsoumi, Nasséra Abermil, Raphaël Degrave, Axelle Schmoll, Matthias Papo, Florence Moinet, Julien Haroche, Miguel Hie, Sophie Bulifon, Z Amoura, Jean-Emmanuel Kahn, Florence Nguyen-Khac, Jennie Okouango Ova, Pierre-Louis Cariou, Damien Roos-Weil
preprint en

Abstract

Erdheim-Chester disease (ECD) is a rare systemic histiocytosis driven by MAPK-pathway mutations, most frequently BRAFV600E. Myeloid neoplasms occur in 10-15% of ECD patients. This is the first report of ECD associated with clonal hypereosinophilic syndrome (HES) in the same patient.A 66-year-old woman was diagnosed with ECD harboring a BRAFV600E mutation concomitantly with HES driven by a TNIP1::PDGFRβ fusion identified by optical genome mapping (OGM). She presented with cutaneous lesions, lymphadenopathy, hypereosinophilia and pulmonary hypertension. Interferon-alpha was discontinued because of disease progression and worsening pulmonary hypertension. Imatinib was attempted but poorly tolerated, resulting in acute heart failure. Cobimetinib resulted in clinical and metabolic improvement of ECD, with limited effect on eosinophilia. Pulmonary hypertension improved after adding tadalafil and bosentan.This case illustrates the interplay between histiocytosis and a coexisting myeloproliferative neoplasm, driven by distinct molecular alterations. BRAF inhibition may cause paradoxical MAPK activation and progression in PDGFRβ-rearranged cells, whereas MEK inhibition with cobimetinib provided an effective and well-tolerated alternative for ECD. OGM was essential for identifying PDGFRβ rearrangement and guiding therapy.We report the first reported case BRAFV600E-mutated ECD associated with HES due to PDGFRβ rearrangement, emphasizing the importance of comprehensive molecular profiling and the therapeutic challenges of managing concurrent clonal hematologic disorders.

Research Square
Université de Versailles Saint-Quentin-en-Yvelines (FR), Sorbonne Université (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Saint-Antoine (FR), Pitié-Salpêtrière Hospital (FR), Bicêtre Hospital (FR)
Good health and well-being
Histiocytic Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon